FOSUN HEALTH Logo

Lymphoma Treatment

catalogue

Lymphoma Treatment

Lymphoma Treatment

Lymphoma treatment is not organised by stage the way solid tumour treatment is. It is organised by subtype, because the same stage number describes two diseases that may be treated in opposite ways — one immediately and with curative intent, the other with careful monitoring and no treatment at all. Read this page alongside the subtype name your biopsy report gives, because that name, more than anything else, determines which of the sections below applies to you.

How the subtype decides the route

The subtype determines four things simultaneously, and they are decided together rather than one after another:

  • Whether to treat now. Aggressive subtypes are treated as soon as staging is complete; several indolent subtypes are monitored, and treatment begins when there is a reason — symptoms, a falling blood count, a large mass or rapid growth.
  • Which regimen. An antibody against CD20 belongs in almost every B-cell lymphoma regimen; a checkpoint inhibitor belongs in Hodgkin lymphoma; asparaginase belongs in NK/T-cell lymphoma of nasal type. These are not interchangeable.
  • Whether treatment is finite or continuous. Many regimens are given for a fixed number of cycles and then stop; mantle cell lymphoma and some indolent subtypes are increasingly managed with continuous oral targeted treatment.
  • Whether transplant or cell therapy is planned. These are options in relapsed disease and, for a few high-risk presentations, part of the first plan.

It is worth noting what does not decide the route. The size of a mass, on its own, does not; a bulky mass in an indolent lymphoma may still be watched. The stage number, on its own, does not; stage IV Hodgkin lymphoma is treated with curative intent. Age does not decide it either, although it changes which regimen is safe. The two findings that carry the most weight are the subtype and how the disease responds to the first part of treatment, which is why the interim scan is built into the plan from the beginning.

Hodgkin lymphoma: treatment adapted to the scan

Hodgkin lymphoma is unusual among cancers in that the treatment is deliberately modified according to how the disease responds, rather than being fixed at the outset. The steps are these:

  • First-line chemotherapy — a combination regimen given in cycles, most commonly containing an anthracycline, bleomycin, vinblastine and dacarbazine. An intensified regimen is used for higher-risk presentations, at the cost of more toxicity.
  • An interim PET-CT — performed after the first part of treatment, because the degree of tracer uptake at that point separates patients who can safely continue on the planned regimen from those whose treatment should be intensified.
  • Radiotherapy where it adds benefit — for limited disease, and for residual masses that remain active on the end-of-treatment scan.
  • Brentuximab vedotin — an antibody against CD30, the marker on Reed-Sternberg cells, used in higher-risk first-line treatment and in relapse.
  • Checkpoint inhibitors — nivolumab and pembrolizumab are unusually active in this disease because of a change on chromosome 9p24.1 that increases the PD-1 ligands on the tumour cells; they are used in relapsed and refractory disease.
  • High-dose chemotherapy with autologous stem cell transplant — for disease that does not respond fully or that returns after first-line treatment.

For a patient the practical conclusion is that the interim scan is not a routine review but the point at which the plan may change. It is therefore worth asking before treatment starts what a good result and a poor result would each bring. And because the regimens in this disease do well, the question is worth putting the other way round as well: if the scan shows an excellent response, is there a version with less radiotherapy, or fewer cycles? That question is entirely reasonable, and it is discussed as a matter of course.

Aggressive B-cell lymphoma: treating to cure

Diffuse large B-cell lymphoma and the related high-grade lymphomas are treated with curative intent from the first cycle, because they grow quickly and respond to treatment in proportion to how quickly they are treated. The approach is as follows:

  • First-line immunochemotherapy — a rituximab-based combination given every three weeks for a fixed number of cycles, with the antibody directed at CD20 and the chemotherapy doing the cytotoxic work.
  • An antibody-drug conjugate added to first-line treatment — for some presentations, a regimen combining an antibody against CD79b with the same chemotherapy backbone is used instead of the standard one.
  • Prophylaxis against involvement of the nervous system — high-dose methotrexate or intrathecal treatment, for patients whose disease sites or markers put them at risk.
  • An end-of-treatment PET-CT — the definitive assessment of whether the disease is in remission, read against a defined threshold rather than as a general impression.
  • CAR T-cell therapy for early relapse — for disease that returns within about a year of finishing first-line treatment, engineered T cells directed at CD19 are the standard approach rather than a second course of chemotherapy followed by transplant.
  • Bispecific antibodies — off-the-shelf alternatives that redirect T cells to the lymphoma, used in relapsed disease when cell therapy is not suitable or not available.

Two points need emphasis. The speed of growth is exactly why waiting is not an option: unlike an indolent lymphoma, a high-grade lymphoma can enlarge noticeably within two weeks, and the interval between diagnosis and the first cycle has a measurable effect on the outcome — which is why the investigations are arranged in parallel rather than one after another. And relapse is not the same thing as progression: a lymphoma that has shrunk but not disappeared entirely, and a lymphoma that is still enlarging during treatment, are assessed differently and lead to different options. That distinction should be stated explicitly when the end-of-treatment scan is discussed.

Indolent lymphoma: when not to treat

Follicular lymphoma, marginal zone lymphoma and small lymphocytic lymphoma behave differently from the aggressive subtypes, and the difference is not a matter of degree. They are often widespread at diagnosis and yet slow, and a substantial proportion of patients receive no treatment at all in the first period:

  • Monitoring at fixed intervals — the initial management for a patient with limited symptoms, no large mass and normal blood counts. It is an active strategy with defined review points rather than an absence of care.
  • Treatment when there is a reason — the triggers are symptoms, a rapidly enlarging or bulky mass, falling blood counts, organ compromise, or the patient's own preference after discussion.
  • Antibody treatment alone or with chemotherapy — an antibody against CD20 is the backbone, given alone or with a chemotherapy combination depending on the burden of disease.
  • Maintenance treatment afterwards — extended antibody treatment after the initial response, which prolongs the interval before further treatment is needed.
  • Immunomodulatory combinations — an oral agent combined with an antibody, used increasingly as an alternative to chemotherapy.
  • Recognising transformation — an indolent lymphoma can acquire the features of an aggressive one, which presents as sudden rapid growth, new symptoms or a rising LDH, and requires a fresh biopsy and treatment as an aggressive lymphoma.

The point that most needs explaining to patients is that monitoring is a treatment decision rather than a delay. In indolent lymphoma, treating earlier has repeatedly been shown not to prolong survival while exposing the patient to the side effects of treatment — which is why a watchful strategy is what the guidelines recommend rather than a compromise. What genuinely cannot be watched without a plan is a change in behaviour: a node that suddenly enlarges, new B symptoms, or a rising LDH are all signals needing immediate reassessment and usually a repeat biopsy, because that is how transformation announces itself.

T-cell and NK/T-cell lymphomas

T-cell and natural killer cell lymphomas are less common than the B-cell group and behave differently enough that they are treated on their own protocols. Several points distinguish them:

  • A regimen designed for B-cell disease may be insufficient — the standard combination used for aggressive B-cell lymphoma produces poorer results in most peripheral T-cell lymphomas, so specific regimens and, in some cases, early transplant are used instead.
  • Extranodal NK/T-cell lymphoma of nasal type — associated with Epstein-Barr virus and more frequent in East Asia, it arises in the nose, nasopharynx or elsewhere and is treated with regimens containing asparaginase combined with radiotherapy to the involved area, because the disease is radiosensitive and the drug is specifically active in it.
  • Anaplastic large-cell lymphoma — divided by whether the ALK gene is rearranged, which separates a form with distinctly better behaviour from one that needs more intensive treatment; an antibody against CD30 is used where the marker is present.
  • Cutaneous T-cell lymphoma — when confined to the skin, treated with skin-directed measures including topical agents, phototherapy and radiotherapy; when the disease extends beyond the skin, systemic treatment is added.
  • Consolidation with transplant in first remission — considered for several aggressive T-cell subtypes in suitable patients, rather than being reserved for relapse.

Because these diseases are uncommon, specialist pathology review is worth relatively more here: a diagnosis made at a centre that handles them regularly is more likely to be classified correctly, and the classification determines a choice of drugs that differs substantially from the standard regimen. If you are given a diagnosis of T-cell lymphoma, it is worth asking how many such cases the treating team handles each year, and whether the pathology has been reviewed by a haemato-pathologist.

Stem cell transplant and CAR T-cell therapy

Two forms of treatment are used when the disease is not controlled by first-line therapy, and patients often ask about them early. Each is a defined tool with specific indications rather than a last resort:

  • Autologous stem cell transplant — the patient's own stem cells are collected and returned after high-dose chemotherapy. It is used for chemosensitive relapse in Hodgkin and aggressive B-cell lymphoma, and as consolidation in some high-risk first remissions. It requires the disease to respond to the chemotherapy given beforehand, which is why it is preceded by a salvage regimen.
  • Allogeneic transplant — stem cells from a donor, used in selected cases where the immune reaction against the lymphoma contributes to control. It carries higher risks, and the decision is made with a transplant specialist rather than as part of a routine pathway.
  • CAR T-cell therapy — the patient's T cells are collected, engineered to recognise CD19, multiplied outside the body and returned. It is the standard approach for B-cell lymphoma that returns early after first-line treatment, and it is also used in later lines.
  • Bispecific antibodies — given as an infusion rather than manufactured for the individual patient, and used where cell therapy is unsuitable, unavailable or has already been given.

What a patient should know in advance, beyond the mechanism, is what the process looks like. CAR T-cell therapy involves a period of collection and manufacture, a short course of lymphodepleting chemotherapy, the infusion itself, and then close monitoring for inflammatory and neurological reactions — reactions that are common, usually reversible and manageable with specific drugs, but which are exactly why this treatment has to be given at a centre equipped to handle them. Long-term follow-up of blood counts and immune recovery is part of the plan too. It is worth asking about the centre's experience with the specific product, the proportion of patients needing intensive care support, and how follow-up would be arranged if you live abroad.

Protecting the nervous system

Lymphoma can involve the brain, the spinal cord or the fluid around them, either at diagnosis or later, and for a defined group of patients measures are taken in advance to prevent it. This is decided from the subtype and the sites of disease rather than from the symptoms:

  • High-grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements — the double-hit and triple-hit group, where the risk is high enough to warrant prophylaxis in most patients.
  • Testicular involvement — a site with a well-recognised propensity for spread to the nervous system.
  • High-risk profiles by index — a high score on the prognostic index, particularly with involvement of the marrow, the epidural space or more than one site outside the nodes.
  • Lymphoma associated with HIV infection, and certain specific subtypes such as Burkitt lymphoma, where prophylaxis is part of the standard regimen.

The method is either a drug that reaches the nervous system when given in high dose by infusion, or treatment given directly into the spinal fluid, or both, depending on the regimen. It is added to the lymphoma treatment rather than substituted for it. Primary lymphoma arising in the central nervous system is a separate situation, treated with drugs that penetrate the brain as the mainstay rather than by the standard lymphoma regimens.

How the treatment plan is decided

The decisions in lymphoma are interdependent, which is why they are settled in a review rather than one at a time. The questions a plan should answer are these:

  • What is the subtype, precisely? Confirmed by immunophenotyping, and reviewed by a specialist where the diagnosis is uncommon or ambiguous.
  • Is treatment indicated now, and if so for how many cycles? With the trigger for starting stated explicitly in the case of an indolent lymphoma.
  • Which specific regimen, and are all its components available? Including any antibody-drug conjugate or targeted agent, and the arrangements for obtaining it.
  • What is the interim assessment, and what would it change? The date of the scan and the threshold at which the plan is modified.
  • What prophylactic measures are needed? Against infection, against tumour lysis, against involvement of the nervous system, and against reactivation of hepatitis B.
  • What happens if the disease returns? The salvage strategy, and whether transplant or cell therapy would be appropriate — stated at the outset rather than improvised later.

Here a written plan is more useful than a verbal explanation, because lymphoma treatment continues for months with decisions being made throughout, and because patients travel between two places. It should state the full subtype, the stage and the risk group, the regimen and its duration, the date and the threshold of the interim assessment, the prophylactic measures, and the arrangements for review after treatment. Send the biopsy report and the block, the immunophenotyping results, the PET-CT images, the treatment already received and the most recent blood results, and the written assessment is returned within 48 hours of the file being complete.

Frequently Asked Questions

Do I have to start treatment immediately?

It depends on the subtype. If you have an aggressive lymphoma such as diffuse large B-cell lymphoma, treatment should begin promptly — these diseases can grow noticeably in a couple of weeks, and the delay costs the chance of cure, so investigations are run in parallel rather than one after another. If you have an indolent lymphoma such as follicular lymphoma, treatment may not be needed at all at first, and monitoring with defined review points is the recommended approach rather than a postponement. What is never appropriate is delay in either group without a plan stating when the next assessment will be and what would trigger treatment.

What does the interim PET scan actually change?

In Hodgkin lymphoma it is used to adjust treatment: a scan showing a good response may allow the planned regimen to continue unchanged or even be reduced, while a poor response is a reason to intensify. In aggressive B-cell lymphoma the value of changing treatment based on an interim scan is less well established, and the end-of-treatment scan carries more weight; the interim scan is still done, but it is interpreted cautiously rather than used to switch regimens automatically. Ask what your team will do with the result in your specific case, because that is the question that determines whether the scan changes anything.

Is a stem cell transplant the same as CAR T-cell therapy?

No, and the difference matters. A stem cell transplant uses high-dose chemotherapy to kill the lymphoma and then rescues the bone marrow by returning stem cells — either the patient's own, collected beforehand, or a donor's. CAR T-cell therapy does not use high-dose chemotherapy at all: it collects the patient's T cells, engineers them to recognise the lymphoma, multiplies them outside the body and returns them, so that the treatment is a living drug. Both are used in relapsed lymphoma, but they are chosen on different criteria, and for lymphoma that returns early after first-line treatment, cell therapy is usually the preferred approach.

Can I have treatment in China and continue at home?

Often yes, and the way to arrange it is to define in advance which parts of the regimen must be given here and which can be continued locally. The first cycles are usually given where the plan is made, because complications and the response assessment happen then; later cycles, and in some indolent lymphomas maintenance doses, can be continued closer to home if the same drugs and the same schedule can be delivered. What makes that work is documentation rather than intention: the regimen, the drugs, the doses, the dates already given and the plan for the next assessment should all be in writing for the clinician who takes over.

Patient Stories

Stories from our lymphoma programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Have your subtype and treatment plan reviewed

Send the biopsy report with the full immunophenotyping panel, the PET-CT images, the treatment already given and the latest blood results. Our haematology team will return a written assessment within 48 hours of the file being complete, including whether the regimen proposed is the standard one for your subtype.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*